Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hematopoietic stem cell transplantation with alpha/beta T-lymphocyte depletion and short course of eculizumab in adolescents and young adults with paroxysmal nocturnal hemoglobinuria.
Shasheleva DA, Maschan AA, Shelikhova LN, Petrova UN, Kurnikova EE, Illarionova OI, Boyakova EV, Novichkova GA, Maschan MA. Shasheleva DA, et al. Among authors: illarionova oi. Ter Arkh. 2018 Aug 17;90(7):57-64. doi: 10.26442/terarkh201890757-64. Ter Arkh. 2018. PMID: 30701923
Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype.
Demina I, Zerkalenkova E, Illarionova O, Olshanskaya Y, Verzhbitskaya T, Semchenkova A, Tsaur G, Rusanova E, Belogurova M, Baidun L, Plyasunova S, Konyuhova T, Kazakova A, Fechina L, Novichkova G, Samochatova E, Myakova N, Maschan A, Popov AM. Demina I, et al. J Cancer Res Clin Oncol. 2019 Nov;145(11):2803-2811. doi: 10.1007/s00432-019-03010-1. Epub 2019 Aug 28. J Cancer Res Clin Oncol. 2019. PMID: 31463716
Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Semchenkova A, Brilliantova V, Shelikhova L, Zhogov V, Illarionova O, Mikhailova E, Raykina E, Skorobogatova E, Novichkova G, Maschan A, Maschan M, Popov A. Semchenkova A, et al. Cytometry B Clin Cytom. 2021 Sep;100(5):568-573. doi: 10.1002/cyto.b.21982. Epub 2020 Dec 28. Cytometry B Clin Cytom. 2021. PMID: 33369016 Free article.
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.
Mikhailova E, Gluhanyuk E, Illarionova O, Zerkalenkova E, Kashpor S, Miakova N, Diakonova Y, Olshanskaya Y, Shelikhova L, Novichkova G, Maschan M, Maschan A, Popov A. Mikhailova E, et al. Haematologica. 2021 Jul 1;106(7):2009-2012. doi: 10.3324/haematol.2019.241596. Haematologica. 2021. PMID: 33375769 Free PMC article.
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E, Semchenkova A, Illarionova O, Kashpor S, Brilliantova V, Zakharova E, Zerkalenkova E, Zangrando A, Bocharova N, Shelikhova L, Diakonova Y, Zhogov V, Khismatullina R, Molostova O, Buldini B, Raykina E, Larin S, Olshanskaya Y, Miakova N, Novichkova G, Maschan M, Popov AM. Mikhailova E, et al. Br J Haematol. 2021 May;193(3):602-612. doi: 10.1111/bjh.17382. Epub 2021 Mar 14. Br J Haematol. 2021. PMID: 33715150
Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Mikhailova E, Roumiantseva J, Illarionova O, Lagoyko S, Miakova N, Zerkalenkova E, Zharikova L, Olshanskaya Y, Novichkova G, Maschan M, Henze G, Karachunskiy A, Popov A. Mikhailova E, et al. Br J Haematol. 2022 Jan;196(1):e6-e9. doi: 10.1111/bjh.17760. Epub 2021 Aug 3. Br J Haematol. 2022. PMID: 34346071 No abstract available.
Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
Mikhailova E, Illarionova O, Shelikhova L, Zerkalenkova E, Molostova O, Olshanskaya Y, Novichkova G, Maschan A, Maschan M, Popov A. Mikhailova E, et al. Haematologica. 2022 Apr 1;107(4):970-974. doi: 10.3324/haematol.2021.279677. Haematologica. 2022. PMID: 34911282 Free PMC article. No abstract available.
Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.
Semchenkova A, Mikhailova E, Komkov A, Gaskova M, Abasov R, Matveev E, Kazanov M, Mamedov I, Shmitko A, Belova V, Miroshnichenkova A, Illarionova O, Olshanskaya Y, Tsaur G, Verzhbitskaya T, Ponomareva N, Bronin G, Kondratchik K, Fechina L, Diakonova Y, Vavilova L, Myakova N, Novichkova G, Maschan A, Maschan M, Zerkalenkova E, Popov A. Semchenkova A, et al. Int J Mol Sci. 2022 Apr 5;23(7):4019. doi: 10.3390/ijms23074019. Int J Mol Sci. 2022. PMID: 35409391 Free PMC article.
14 results